Description
Product Name: Tirzepatide Molecular Formula: C225H348N48O68 Molar Mass: ~4813.53 g/mol Sequence: Y-{Aib}-E-G-T-F-T-S-D-Y-S-I-{Aib}-L-D-K-I-A-Q-K(C20-diacid-gamma-Glu-bis-AEEA)-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2
Product Overview Tirzepatide is a “first-in-class” dual agonist, often referred to as a “twincretin.” While Semaglutide targets only the GLP-1 receptor, Tirzepatide is engineered to activate both the GLP-1 and GIP receptors. The peptide backbone is derived from the GIP sequence but modified to bind GLP-1 receptors with comparable affinity. It features a specific lipophilic side chain (a C20 fatty diacid attached via a hydrophilic linker) at the lysine residue in position 20, which facilitates binding to plasma albumin and protects the peptide from rapid enzymatic degradation.
Mechanism of Action Tirzepatide mimics the action of the two key incretin hormones, GIP and GLP-1, promoting a synergistic modulation of metabolism:
-
GIP Receptor Activation: Enhances insulin secretion in a glucose-dependent manner and is believed to improve lipid metabolism and adipose tissue function. Unlike GLP-1 alone, GIP activation may improve insulin sensitivity directly in adipose tissue.
-
GLP-1 Receptor Activation: Slows gastric emptying, suppresses glucagon secretion, and signals satiety in the central nervous system.
-
Synergy: In research models, the simultaneous activation of both receptors has been shown to result in greater reductions in body weight and blood glucose levels compared to agents that target either receptor in isolation.
Research Applications Tirzepatide is a primary subject of investigation in high-impact metabolic research, particularly for:
-
Obesity and Weight Management: Examining the “supra-additive” effects of dual agonism on adipose mass reduction.
-
Type 2 Diabetes: Studying the restoration of first-phase insulin secretion and the preservation of pancreatic beta-cell function.
-
Hepatology: Investigating potential reductions in liver fat content and biomarkers associated with Non-Alcoholic Steatohepatitis (NASH).
-
Lipidomics: Analyzing changes in triglyceride clearance and lipid profiles under dual-agonist conditions.
Storage and Handling
-
Storage: Store lyophilized powder at 2-8°C. Reconstituted solutions should be kept at 4°C and used promptly.
-
Stability: Stable for 2 years when stored properly in lyophilized form. Hygroscopic; keep container tightly sealed.
Disclaimer: This material is sold for research and development purposes only. It is not intended for human ingestion, diagnostic, therapeutic, or clinical procedures. All research must be conducted by qualified professionals in a laboratory setting.
